Bone metastases occur in more than 1.5 million patients with cancer worldwide and are most commonly associated with cancers of the prostate, lung, and breast, with incidence rates as high as 90 percent of patients with metastatic disease — Approximately 50-70 percent of cancer patients with bone metastases will experience debilitating Skeletal-Related Events, which include fractures, spinal cord compression and severe bone pain that may require surgery or radiation— Such events can profoundly disrupt a patient’s life and can cause disability and pain — I’m Christina Collins with CRWE Newswire — Today’s company highlight is Amgen Incorporated trading with the symbol AMGN —Amgen discovers, develops, manufactures and delivers innovative human therapeutics — Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses — Amgen recently reported primary results of a pivotal Phase 3 trial ‘147 demonstrating that XGEVA (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone — Study 147 was a randomized, placebo-controlled, multi-center Phase 3 study comparing the treatment effect of XGEVA to placebo in prolonging bone metastasis-free survival - a measure of the time that patients live without progressing to bone metastases - in 1,432 men with hormone-refractory ,castrate-resistant, prostate cancer with rapidly-rising prostate-specific antigen levels who had no bone metastases at baseline — XGEVA is the first and only RANK Ligand inhibitor approved by the U.S. Food and Drug Administration indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Amgen has submitted marketing applications for XGEVA in the European Union, Australia, and Switzerland for the prevention of SREs in patients with bone metastases from solid tumors—With effective therapies now in place for both early castrate-sensitive prostate cancer and advanced castrate-resistant prostate cancer, there is a gap in the treatment plan for those patients who are castrate-resistant but have not yet developed metastatic disease — For more information about Amgen Incorporated, symbol AMGN, visit amgen.com — I’m Christina Collins with CRWE Newswire
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer
) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.